Tocagen Inc (NASDAQ:TOCA) Receives Consensus Rating of “Buy” from Analysts

Share on StockTwits

Tocagen Inc (NASDAQ:TOCA) has received a consensus recommendation of “Buy” from the eleven analysts that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $14.46.

Several analysts have recently weighed in on the stock. Leerink Swann set a $5.00 price target on shares of Tocagen and gave the company a “hold” rating in a research note on Wednesday, May 22nd. Chardan Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Tocagen in a research note on Wednesday, May 22nd. ValuEngine raised shares of Tocagen from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research raised shares of Tocagen from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a research note on Wednesday. Finally, Cantor Fitzgerald assumed coverage on shares of Tocagen in a research note on Thursday, April 25th. They set an “overweight” rating and a $28.00 price target for the company.

In other Tocagen news, Director Faheem Hasnain acquired 43,000 shares of Tocagen stock in a transaction that occurred on Thursday, May 30th. The stock was bought at an average price of $4.66 per share, with a total value of $200,380.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders purchased 53,000 shares of company stock valued at $244,880 in the last three months. 10.90% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of the stock. BlackRock Inc. grew its holdings in shares of Tocagen by 6.2% during the 4th quarter. BlackRock Inc. now owns 1,501,501 shares of the company’s stock worth $12,327,000 after purchasing an additional 88,216 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Tocagen by 7.7% during the 4th quarter. Bank of New York Mellon Corp now owns 56,938 shares of the company’s stock worth $468,000 after buying an additional 4,093 shares during the last quarter. Northern Trust Corp lifted its position in shares of Tocagen by 9.7% during the 4th quarter. Northern Trust Corp now owns 223,113 shares of the company’s stock worth $1,831,000 after buying an additional 19,721 shares during the last quarter. Stifel Financial Corp lifted its position in shares of Tocagen by 34.0% during the 4th quarter. Stifel Financial Corp now owns 26,392 shares of the company’s stock worth $215,000 after buying an additional 6,698 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Tocagen by 24.2% during the 4th quarter. Geode Capital Management LLC now owns 211,795 shares of the company’s stock worth $1,738,000 after buying an additional 41,261 shares during the last quarter. 35.06% of the stock is owned by institutional investors.

Shares of Tocagen stock traded up $0.04 on Friday, hitting $4.34. 4,543 shares of the company traded hands, compared to its average volume of 174,162. The company has a 50 day moving average of $5.58. The company has a debt-to-equity ratio of 0.75, a quick ratio of 5.05 and a current ratio of 5.05. Tocagen has a 52 week low of $4.12 and a 52 week high of $15.80. The stock has a market cap of $112.56 million, a P/E ratio of -1.78 and a beta of 3.90.

Tocagen (NASDAQ:TOCA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.72) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.76) by $0.04. Tocagen had a negative net margin of 300.42% and a negative return on equity of 107.89%. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.50 million. On average, analysts forecast that Tocagen will post -2.78 EPS for the current fiscal year.

Tocagen Company Profile

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Featured Story: Trading Ex-Dividend

Analyst Recommendations for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.